S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   147.17 (-1.84%)
NVDA   769.00 (-9.18%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.42 (+0.55%)
F   12.11 (+0.41%)
MU   106.73 (-4.65%)
GE   148.53 (-2.88%)
CGC   7.99 (+2.04%)
DIS   112.27 (-0.14%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.84 (+1.11%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   147.17 (-1.84%)
NVDA   769.00 (-9.18%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.42 (+0.55%)
F   12.11 (+0.41%)
MU   106.73 (-4.65%)
GE   148.53 (-2.88%)
CGC   7.99 (+2.04%)
DIS   112.27 (-0.14%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.84 (+1.11%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   147.17 (-1.84%)
NVDA   769.00 (-9.18%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.42 (+0.55%)
F   12.11 (+0.41%)
MU   106.73 (-4.65%)
GE   148.53 (-2.88%)
CGC   7.99 (+2.04%)
DIS   112.27 (-0.14%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.84 (+1.11%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   147.17 (-1.84%)
NVDA   769.00 (-9.18%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.42 (+0.55%)
F   12.11 (+0.41%)
MU   106.73 (-4.65%)
GE   148.53 (-2.88%)
CGC   7.99 (+2.04%)
DIS   112.27 (-0.14%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.84 (+1.11%)
Free Trial

Gilead Sciences (GILD) Stock Forecast & Price Target

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free gild Stock Alerts
$66.50
+0.34 (+0.51%)
(As of 03:22 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Gilead Sciences Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$84.71
27.39% Upside
High Forecast$105.00
Average Forecast$84.71
Low Forecast$71.00
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$84.71$85.36$86.87$89.60
Predicted Upside27.39% Upside13.21% Upside10.02% Upside10.62% Upside
Get Gilead Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

GILD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gilead Sciences Stock vs. The Competition

TypeGilead SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.27
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside27.85% Upside928.36% Upside12.32% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/19/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$105.00+58.01%
4/17/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$81.00 ➝ $75.00+12.06%
3/4/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$84.00 ➝ $77.00+6.49%
2/22/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$101.00 ➝ $90.00+24.76%
2/22/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$91.00 ➝ $82.00+12.02%
2/14/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetSector Perform ➝ Sector Perform$76.00 ➝ $75.00+2.25%
2/12/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$85.00 ➝ $80.00+7.86%
2/7/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$80.00 ➝ $78.00+4.06%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold$75.00-3.72%
10/11/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingMarket Perform
9/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$88.00 ➝ $95.00+28.48%
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageReduce$71.00-5.53%
8/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$86.00 ➝ $88.00+10.15%
7/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$105.00 ➝ $100.00+26.34%
7/18/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$100.00 ➝ $95.00+22.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:45 PM ET.

GILD Price Target - Frequently Asked Questions

What is Gilead Sciences's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Gilead Sciences stock is Hold based on the current 1 sell rating, 9 hold ratings and 5 buy ratings for GILD. The average twelve-month price prediction for Gilead Sciences is $84.71 with a high price target of $105.00 and a low price target of $71.00. Learn more on GILD's analyst rating history.

Do Wall Street analysts like Gilead Sciences more than its competitors?

Analysts like Gilead Sciences less than other Medical companies. The consensus rating for Gilead Sciences is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how GILD compares to other companies.

Is Gilead Sciences being downgraded by Wall Street analysts?

Over the previous 90 days, Gilead Sciences's stock had 1 downgrade by analysts.

Does Gilead Sciences's stock price have much upside?

According to analysts, Gilead Sciences's stock has a predicted upside of 14.32% based on their 12-month stock forecasts.

What analysts cover Gilead Sciences?

Gilead Sciences has been rated by Barclays, Cantor Fitzgerald, Mizuho, Oppenheimer, Royal Bank of Canada, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:GILD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press